The FDA's fast track designation acknowledges the combination's promising early efficacy and safety profile in treating MSS mCRC. Early data from a phase 1b/2 study showed deep, durable responses with ...

Insider.comNews Commentary – The FDA is moving to require just one clinical trial for new drug approvals, signaling a dramatic shift toward faster regulatory pathways that could accelerate oncology ...

Shares of Adagene Inc. (NASDAQ:ADAG) jumped more than 16% in pre-market trading on Tuesday after the biotech company said the ...

The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the ...

In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor.

Older Americans with metastatic breast, colorectal, lung, or prostate cancer are spending an increasing amount of time in the ...

Memorial Sloan Kettering Cancer Center researchers continued to make strides against cancer in 2025. Learn about some of ...

Scientists have discovered that routine scans taken during prostate cancer radiotherapy may do more than just help guide ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...